Company news

Evogene Ltd. (NASDAQ:EVGN) news

Evogene Ltd. news releases on 6ix. Latest, Oct 6, 2026: Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute…

Evogene Ltd. (NASDAQ:EVGN) news

Press releases & updates

Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance

Evogene Responds to Dissident Shareholders: Transformation and Commercial Progress Provide a Clear Path Forward

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Evogene Ltd. Shareholders Vote "FOR" the Company's Slate of Highly Qualified Director Nominees

Evogene Reports Second Quarter and First Half 2026 Financial Results

Evogene Chairman Nir Nimrodi to Join Quarterly Results Call to Address Current Dissident Shareholders Situation

Evogene Schedules Second Quarter 2026 Financial Results Release

Evogene Ltd. and ELEO Inc. Announce Collaboration to Develop Next-Generation Oral Small-Molecule PCSK9 Pathway Inhibitors for Hyperlipidemia and Cardiovascular Diseases

AgPlenus Launches Novel AI Model for Predicting Antifungal Potency, Expanding ChemPass AI for Ag™ Capabilities

Evogene and Tel Aviv University's Blavatnik Center for Drug Discovery Announce Joint Initiative to Accelerate AI-Driven Small-Molecule Drug Discovery

Evogene Announces Major Milestone in Its Collaboration with Google Cloud, Advancing ChemPass AI™ Toward Autonomous Small Molecule Discovery and Optimization

Evogene to Present Its Pharma Division Achievements at the BIO International Convention

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

Evogene Reports First Quarter 2026 Financial Results

Evogene to Present at the 24th Schrödinger European User Group Meeting

Evogene Schedules First Quarter 2026 Financial Results Release

Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification

Casterra Announces Successful Commercial Field Trials in Brazil, Positioning Castor Oil as a Promising Candidate for Economically Viable Biofuel Feedstock

Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Evogene Reports Fourth Quarter and Full Year 2025 Financial Results

Evogene Releases CEO Letter to Shareholders

Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release

Evogene and Queensland University of Technology (QUT) Announce a Collaboration to Advance AI-Driven Cancer Therapeutics

Evogene, Systasy and LMU University Hospital Munich Announce a Collaboration to Develop Novel Therapies for Neutrophil-Derived Inflammatory Diseases

Evogene Announces a Warrant Inducement Transaction for Approximately $3.4 Million of Gross Proceeds

Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™

Evogene Appoints Prof. John Irwin and Prof. Dan Major to its Scientific Advisory Board

Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer

Evogene and Unravel Biosciences Announce Collaboration to Develop a First-in-Class Therapy to Reverse Neurological Damage in Demyelinating Disorders

Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development

Evogene Reports Third Quarter 2025 Financial Results

Casterra and Fantini Partner to Advance Agricultural Mechanization for Scalable Commercial Castor Farming

Evogene Schedules Third Quarter 2025 Financial Results Release

Evogene to Present at H.C. Wainwright 27th Annual Global Investment Conference in New York

Evogene Reports Second Quarter 2025 Financial Results

Evogene and Professor Ehud Gazit of Tel Aviv University Announce a Collaboration to Develop New Therapeutics for Metabolic Diseases

Evogene Schedules Second Quarter 2025 Financial Results Release

Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL

Evogene Announces Completion of First-In-Class Foundation Model for Generative Molecule Design, Developed in Collaboration with Google Cloud

Evogene Reports First Quarter 2025 Financial Results

Evogene Schedules First Quarter 2025 Financial Results Release

ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio

Evogene Reports Fourth Quarter and Full Year 2024 Financial Results

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Evogene Schedules Fourth Quarter 2024 Financial Results Release

Evogene Reports Third Quarter 2024 Financial Results

Evogene Schedules Third Quarter 2024 Financial Results Release

Evogene Announces Collaboration with Google Cloud to Pioneer Generative AI Foundation Model for Novel Small Molecule Design

Evogene Announces Pricing of US$5.5 Million Registered Direct Offering and Concurrent Private Placement